TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Multiple sclerosis \[MS\] subject who was ambulatory (EDSS of ≤ 5.5)~* Exhibiting a relapsing clinical course, with or without progression (relapsing remitting, secondary progressive or progressive relapsing);~* Meeting McDonald's criteria for MS diagnosis;~* Experienced at least 1 relapse over the 1 year preceding the trial or at least 2 relapses over the 2 years preceding the trial;~* No relapse onset in the preceding 60 days prior to randomization;~* Clinically stable during the 30 days prior to randomization, without adrenocorticotrophic hormone \[ACTH\] or systemic steroid treatment.~Exclusion Criteria:~* Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease;~* Significantly impaired bone marrow function;~* Pregnant or nursing woman;~* Alcohol or drug abuse;~* Use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment;~* Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Teriflunomide 7 mg (Type: EXPERIMENTAL): Teriflunomide 7 mg once daily for 108 weeks
- Teriflunomide 14 mg (Type: EXPERIMENTAL): Teriflunomide 14 mg once daily for 108 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for teriflunomide) once daily for 108 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fetal and Infant Effects of Maternal Buprenorphine Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Current opioid dependence as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM) IV-R criteria~* 18-40 years of age with uncomplicated singleton pregnancies~* Accurate gestational age dating verified by ultrasound~* Gestation of less than 34 weeks~* Stabilization on buprenorphine for one week prior to study procedures~Exclusion Criteria:~* Complications of pregnancy, including gestational diabetes, polyhydramnios, hypertension, placenta previa or significant risk of preterm delivery (i.e. incompetent cervix)~* Evidence of fetal malformation detected by prenatal ultrasound~* Significant general maternal health problems that can affect fetal functioning, including Type I or gestational diabetes, alterations in thyroid functioning, HIV infection or hypertension.~* Significant maternal psychopathology that would preclude informed consent (i.e. schizophrenia)~* Alcohol dependency per DSM IV R criteria (see ascertainment methods below)~* Women stable on methadone maintenance (defined as more than 3 days of methadone dosing)~* Women entering drug treatment reporting using street methadone (for more than 3 days)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Maternal buprenorphine treatment (Type: EXPERIMENTAL): Buprenorphine maintenance during pregnancy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of IL-1 Beta on the HPA-axis in Obese Persons

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80 years~* BMI \>30kg/m2 and at least 1 manifestations of the metabolic syndrome (i.e. diabetes/ prediabetes, hypertension, dyslipidemia)~* Willingness to use contraceptive measures adequate to prevent becoming pregnant~Exclusion Criteria:~* Medication with glucocorticosteroids~* Known Cushing Syndrome~* Pregnancy or breast feeding~* Clinical signs of infection in the week before inclusion or history of a severe infection during the last 2 months~* Hematologic disease (leukocyte count \< 1.5x109/l, hemoglobin \<11 g/dl, platelets \<100 x 103/ul)~* Kidney disease (creatinine-clearance \< 30ml/min))~* Liver disease (transaminases \>4x upper normal range)~* Active carcinoma~* History of tuberculosis~* Alcohol consumption \>40g/d for men, \>30g/d for women~* Known allergy towards anakinra~* Subject refusing or unable to give written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): Anakinra 100mg s.c. x 5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-65 years of age~* Who have given written informed consent after the nature of the study has been explained.~* Who work within the Manchester Medical Microbiology Partnership and may be at potential occupational exposure to meningococci.~Exclusion Criteria:~* The possibility of pregnancy~* A serious chronic disease including progressive neurological disease or seizure disorder.~* Have a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.~* Have a history of severe allergic reactions after previous vaccinations such as anaphylactic shock, asthma, urticaria, or other allergic reaction or hypersensitivity to any vaccine component.~* Have received another investigational agent within 90 days or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another investigational trial through the end of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intracervical Block Versus Placebo to Assess Pain Control During Hysterosalpingogram

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients without a known cause for their infertility who were undergoing a hysterosalpingogram were eligible for enrollment.~* All subjects were 18 to 40 years of age and married.~Exclusion Criteria:~* Included a history of any allergies to local anesthetics, radio-opaque dye or to anti-inflammatory medications.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female volunteers 19-65 years old~* Females must be nonlactating and nonpregnant (negative serum pregnancy test at screening)and agree to practice effective birth control for at least 30 days after study completion~* Nonsmoker or no tobacco/nicotine use in previous 6 months~* Intact normal skin without obscuring tattoos, pigmentation or lesions~* Adequate venous access in upper extremities~* Normal vital signs, ECG, and labs or assessed by the Investigator as NCS~* Serum hemoglobin within site's normal range~* Negative drug and alcohol screen~* Able to make decisions and comply with study requirements~Exclusion Criteria:~* History of drug or alcohol abuse or positive drug and alcohol screen~* Abdominal surgery within the last 30 days~* Phenylketonuria~* Tobacco or nicotine use within previous 6 months~* Hypersensitivity or contraindication to ondansetron or other 5-HT3 receptor agonists~* Received ondansetron within 4 days prior to Day 1~* Known allergy to hyaluronidase or other ingredient in Hylenex recombinant~* Lower extremity edema~* Creatinine clearance \< 60 mL/min~* Dehydration (Grade 2 or higher)~* Hypersensitivity or contraindication to heparin~* Abnormal ECG with clinically significant QT prolongation or history of~* Female who is pregnant or breastfeeding~* Participation in a clinical trial (drug or device) within 30 days of enrollment~* Clinically significant medical history, major systemic disease, intercurrent illness, physical examination finding, or clinical laboratory test result that risks the subject's safety or interfere with interpretation of study results~* Not able to comply with study requirements

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Subcutaneous Administration (Type: EXPERIMENTAL): Ondansetron + Hylenex administered subcutaneously
- Oral Administration (Type: EXPERIMENTAL): Ondansetron administered orally
- Intramuscular Administration (Type: EXPERIMENTAL): Ondansetron administered intramuscularly
- Intravenous Administration (Type: EXPERIMENTAL): Ondansetron administered intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Percutaneous Lumbar Epidural Adhesiolysis and Neurolysis on Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years of age~* History of chronic, function limiting low back pain of at least 6 months in duration~* Able to give voluntary, written informed consent~* Able to understand investigational procedures and willing to return for follow-ups~* No recent surgical procedures within last 3 months~Exclusion Criteria:~* Large contained or sequestered herniation~* Cauda Equina symptoms and/or compressive radiculopathy~* Narcotic use of no greater than 100mg/day Hydrocodone, 60mg Methadone, or 100mg Morphine~* Uncontrolled major depression or psychiatric disorder~* Uncontrolled or acute medical illness~* Chronic sever conditions that could interfere with outcome assessments~* Women who are pregnant or lactating~* Subjects who have participated in a clinical study with an investigational product within 30 days of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caudal epidural injection (Type: ACTIVE_COMPARATOR): Caudal epidural with placement of catheter in sacral canal with injection of 5 mL of 2% preservative-free lidocaine, followed by 6 mL of 0.9% sodium chloride solution and 6 mg of non-particulate Betamethasone and 1 mL of sodium chloride solution
- Percutaneous adhesiolysis (Type: ACTIVE_COMPARATOR): Pecutaneous adhesiolysis and targeted placement of Racz catheter with injection of 5 mL of 2% preservative-free lidocaine, followed by 6 mL of 10% sodium chloride solution and 6 mg of non-particulate Betamethasone and 1 mL of sodium chloride solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must provide signed inform consent prior to participation.~* BMI between 19,5 y 29 kg/m2.~* Normal ocular test in both eyes: IOP \</=21 mmHg. BCVAof \>/=0,8 (20/25)Snellen scale, or \</=0.1 LogMar.~* Normal fluorescein Clearance Test in both eyes.~* Normal funduscopy in both eyes.~Exclusion Criteria:~* Pregnant or breastfeeding females or those with a positive pregnancy test or who will not use a medically acceptable contraceptive method from selection and during the study.~* Current relevant disease.~* Previous chronic processes or with rebound characteristics that could interfere with study according investigator's judgment.~* Volunteers who have received pharmacological treatment, including medicinal plants, during the four weeks previous to beginning the study.~* Having used corticoids sporadically in the last 30 days whichever the route aof administration, or any med by ocular or nasal administration route.~* Case history of hypersensitivity to meds or any other allergic process.~* Visual alterations: previous eye surgery, glaucoma, use of lenses, uveitis or ocular surface pathology (dry eye, blepharitis).~* Volunteers with visual alteration with more than 3 dioptres in either eye.~* Volunteers who has participated in a clinical trial during the past fout months before study entry.~* Blood or derivate transfusion during the six previous months to study entry.~* Case history of drug or alcohol abuse or dependence.~* Positive result in test drug abuse during selection period.~* positive serology results to hepatitis B virus(HbsAg), virus C o VIH.~* Analytic alterations medically relevant, at investigator's judgement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- SYL1001 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mnemonic Strategy Versus Spaced Retrieval Training in Those With Mild Cognitive Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-Diagnosis of MCI according to Petersen (2004) criteria, right handed~Exclusion Criteria:~* Diagnosis of other neurological condition,~* active drug/alcohol abuse/dependence,~* moderate-severe depression or other Axis I diagnoses.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mnemonic strategy training (Type: EXPERIMENTAL): Training using mnemonic strategies
- Spaced retrieval training (Type: ACTIVE_COMPARATOR): Training using spaced retrieval

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female ≥3 years to ≤50 years~2. Good general health by medical history physical examination, baseline electrocardiographs and laboratory tests.~3. No clinically relevant abnormalities in blood pressure and heart rate~4. No clinically relevant abnormalities in 12-lead ECG results\*~   \*Patients with a QTcB or QTcF greater than 450 ms or clinically significant abnormalities of rhythm at Screening are not eligible. Patients with a pre-dose baseline value \> 450 ms should be withdrawn from the study prior to dosing.~   Exclusion Criteria:~5. A history of additional risk factors for Torsades-des-Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome);~6. The use of concomitant medications that prolong the QT/QTc interval;~7. Any condition requiring regular concomitant medication, including herbal products and over-the-counter (OTC) medication or predicted need of any concomitant medication during the study;~8. History of relevant clinical allergic reactions of any origin;~9. Any other condition that in the opinion of the Investigator would interfere with the evaluation of the results or constitute a health risk for the subject;~10. Patients who are not willing to give informed consent (patient and/or parent/legal representative), or who withdraw consent.~11. Pregnant women in the 1st trimester of pregnancy.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Dihydroartemisinin-piperaquine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Respiratory Impedance and Obliterative Bronchiolitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* consecutive, clinically-stable, outpatients undergoing allogeneic HSCT (sourcing from bone marrow) for hematological malignancies~* values of standard PFTs within normal range before HSCT~* good collaboration during the maneuvers~Exclusion Criteria:~* patients showing any spirometric and/or volumetric abnormality before HSCT~* poor collaboration and/or coordination during the maneuvers~* any clinically-significant respiratory disease (bronchial asthma, COPD, cystic fibrosis, etc.) before HSCT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- albuterol (Type: EXPERIMENTAL): Twenty-six consecutive patients undergoing allogeneic HSCT for hematological malignancies were studied. All patients were in stable clinical conditions at the time of study. All patients received a myeloablative conditioning regimen either including or not including total body irradiation. Spirometry, lung volumes, FOT and lung CT scan were obtained before the start of conditioning treatment and, approximately, two months after HSCT. On each study day, all the above measurements were taken before and 30 min after inhaling four consecutive albuterol doses, of 100 mcg each, through a valved-holding chamber. DLco was measured only after bronchodilator inhalation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 18-75 years old~* Currently meet the DSM-IV-TR criteria for Major Depressive Disorder~* The patient's current depressive episode must be at least 6 weeks in duration~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control.~* Patients who are considered a suicide risk~* Patients with a history of meeting DSM-IV-TR criteria for~* a. any manic or hypomanic episode~* b. schizophrenia or any other psychotic disorder~* c. obsessive-compulsive disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 40mg Levomilnacipran ER
- 2 (Type: EXPERIMENTAL): 80mg of Levomilnacipran ER
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Is a premenopausal female aged 18 to 50 years old (inclusive) on the day of signing of the informed consent form.~2. Has agreed to use only study-specified analgesic medications during the study and is not known to be intolerant to these.~3. Has a diagnosis of endometriosis and has had, within 10 years prior to signing the informed consent form, surgical or direct visualization and/or histopathologic confirmation of endometriosis, for example, during a laparoscopy or laparotomy.~4. During the Run-In Period (35 to 70 days prior to treatment period) has a dysmenorrhea NRS score ≥ 4.0 on at least 2 days and~   1. Mean NMPP NRS score ≥ 2.5, or~  2. Mean NMPP NRS score ≥ 1.25 and NMPP NRS score ≥ 5.0 on ≥ 4 days.~Key Exclusion Criteria:~1. Has a history of chronic pelvic pain that is not caused by endometriosis.~2. Has any chronic pain or frequently recurring pain condition, other than endometriosis that is treated with opioids or requires analgesics for ≥ 7 days per month.~3. Has had surgical procedures for treatment of endometriosis within the 3 months prior to the Screening visit.~4. Has a history of or currently has osteoporosis or other metabolic bone disease.~5. Has a clinically significant gynecologic condition, other than endometriosis, identified during Screening or Run-In period transvaginal ultrasound or endometrial biopsy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Relugolix plus E2/NETA (Group A) (Type: EXPERIMENTAL): Relugolix co-administered with E2/NETA for 24 weeks.
- Relugolix plus Delayed E2/NETA (Group B) (Type: EXPERIMENTAL): Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
- Placebo (Group C) (Type: PLACEBO_COMPARATOR): Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete